Trial · NCT07905027
A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML
NCT07905027, Phase 1, Not yet recruiting, Seattle Children's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML. Trials, record NCT07905027. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905027
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML
- NCT number
- NCT07905027
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Seattle Children's Hospital
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukaemia Recurrent, Acute Myeloid Leukaemia Refractory
- Interventions
- Biological SC-CAR.CLEC2Av1
- First posted
- 2026-10-29
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants experiencing Dose Limiting Toxicities (DLTs) and treatment-related adverse events as assessed by NCI CTCAE v6.0, ASTCT CRS/ICANS scales, and IEC-HS grading. | 28 days post-infusion | Evaluation of safety, tolerability, and full toxicity profile following a single infusion of SC-CAR.CLEC2Av1 CAR T cells. DLTs are evaluated within 28 days post-infusion to determine the Maximum Tolerated Dose (MTD) or Biologically Effective Dose (BED). Toxicities will be graded using NCI CTCAE v6.0 for general non-hematologic/hematologic toxicities, protocol-specific scales for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and ASTCT consensus guidelines for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS). |
| Primary | The feasibility of manufacturing SC-CAR.CLEC2Av1 CAR T cells from children and adults with relapsed or refractory CLEC2A+ AML. | 28 days | |
| Secondary | Number of participants with persistence of the SC-CAR.CLEC2Av1 CAR T-Cells | 42 days post-infusion. | Patients will be followed for 42 days to determine if the transferred T-cells remain detectable in the blood, bone marrow, and cerebrospinal fluid. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905027
GET https://conductscience.org/api/trials/v1/NCT07905027/registered